Clinics in dermatologySep 2, 2026

GLP-1 Receptor Agonists as Treatments for Skin Conditions Linked to Other Diseases

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 3, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may improve outcomes in psoriasis and hidradenitis suppurativa while reducing related metabolic and cardiovascular issues.

GLP-1RAs have been linked to weight reduction and glycemic control, which are critical for managing obesity and type 2 diabetes.
Combination therapy with tirzepatide in psoriasis has shown enhanced skin clearance and a decreased risk of developing psoriatic arthritis.
In hidradenitis suppurativa, GLP-1RAs are associated with better cardiometabolic outcomes and fewer systemic complications.
The therapeutic benefits of GLP-1RAs may primarily address underlying metabolic dysfunction and systemic inflammation rather than directly targeting skin inflammation.
Current evidence suggests an evolving role for GLP-1RAs as immune-metabolic therapies in treating inflammatory skin diseases.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of obesity, type 2 diabetes mellitus, and cardiometabolic disease through effects on weight reduction, glycemic control, and systemic inflammation. Their varied immunometabolic actions have generated increasing interest in dermatology, where chronic inflammatory skin diseases frequently coexist with obesity, insulin resistance, metabolic syndrome, and cardiovascular disease. Emerging evidence from clinical trials, observational studies, and real-world analyses suggests that GLP-1RAs may improve outcomes in psoriasis and hidradenitis suppurativa while simultaneously reducing the burden of associated metabolic and cardiovascular comorbidities. In psoriasis, combination therapy with tirzepatide has demonstrated enhanced skin clearance, substantial weight loss, and reduced risk of psoriatic arthritis. In hidradenitis suppurativa, GLP-1RAs have been associated with improvements in cardiometabolic outcomes and reductions in systemic complications. Collectively, these findings support an evolving paradigm in which the greatest therapeutic utility of GLP-1RAs in dermatology may lie not in direct modulation of cutaneous inflammation but in addressing the metabolic dysfunction and chronic systemic inflammation that drive disease severity and multimorbidity. We review the current clinical evidence and propose a conceptual framework positioning GLP-1RAs as immune-metabolic therapies that target the systemic comorbidities of inflammatory skin disease, which may provide future opportunities for cutaneous disease modification and integrated dermatologic care.

Full Text

Full text is available at the source.

View Full Text ↗

GLP-1 Receptor Agonists as Treatments for Skin Conditions Linked to Other Diseases

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief